EMA committee recommends 13 medicines for approval in January meeting
The committee for human medicinal products recommended AstraZeneca’s COVID-19 vaccine be granted conditional marketing authorisation alongside 12 other approvals.
List view / Grid view
News
AstraZeneca to provide EU with extra nine million doses of COVID-19 vaccine following dispute
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
UK Government orders 100 million doses of Valneva COVID-19 vaccine
The UK Government has ordered a further 40 million doses of Valneva’s COVID-19 vaccine candidate, to be manufactured in Scotland.
AI to be most transformative technology for pharma, finds survey
A new report suggests artificial intelligence (AI) will be the most disruptive technology in the pharmaceutical industry this year and beyond.
CEPI offers $140 million to support research on COVID-19 vaccines
CEPI has opened a new funding opportunity, providing up to $140 million to support additional clinical research on COVID-19 vaccines.
Valneva begins manufacturing its inactivated, adjuvanted COVID-19 vaccine
The company announced that the Phase I/II trial for VLA2001 is now fully enrolled and that it has begun manufacturing the vaccine candidate on an industrial scale.
Sotorasib shows success against non-small cell lung cancer in Phase II trial
In a Phase II trial, sotorasib was shown to be effective against pre-treated non-small cell lung cancer (NSCLC).
Study finds some antibody therapies are not effective against new COVID-19 variants
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lilly’s bamlanivimab, were not.
Europe approves KEYTRUDA® as first-line therapy in certain colorectal cancers
The European Commission approval makes KEYTRUDA® (pembrolizumab) the first anti-PD-1 therapy approved for metastatic microsatellite instability-high (MSI-H) colorectal cancer patients in Europe.
Vaccine delivered via skin scarification could help fight respiratory diseases
According to a new study, vaccines delivered via skin scarification were better at inducing T cell activity in pre-clinical animal models.
EMA accepts MAA for Oxbryta to treat haemolytic anaemia in sickle cell disease
The EMA has accepted Global Blood Therapeutics' marketing authorisation application for Oxbryta (voxelotor) to treat haemolytic anaemia in sickle cell disease.
Lilly’s antibody combo reduces COVID-19 hospitalisations and risk of death by 70 percent
Data from a Phase III trial shows high-risk patients treated with bamlanivimab and etesevimab were 70 percent less likely to be hospitalised due to COVID-19.
REGEN-COV prevents symptomatic COVID-19 infections, finds analysis
Interim data from the Phase III trial evaluating REGEN-COV™ as a passive vaccine to prevent COVID-19 finds it reduces overall infection rate, viral load and length of infection.
Moderna COVID-19 vaccine successful against emerging variants, study shows
Results from in vitro neutralisation studies have shown that Moderna's COVID-19 vaccine is effective against emerging strains of SARS-CoV-2.
IGV-001 demonstrates success against glioblastoma in Phase Ib trial
Imvax's Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma has shown positive results.
